Astria Therapeutics's receivables is $17M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
Astria Therapeutics (ATXS) currently reports a receivables of $17M as of September 2025. In the prior-year period, the figure was $0. Use the charts on this page to explore Astria Therapeutics's receivables history and peer comparisons.
Astria Therapeutics's receivables changed from $0 to $17M (period ending September 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Astria Therapeutics reported $17M in receivables as of September 2025. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current receivables of $17M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Astria Therapeutics, and consider following ATXS for alerts when major investors trade the stock.
Astria Therapeutics is classified in the Healthcare sector. On receivables, it currently shows $17M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ATXS with unrelated industries.